Physician profile
Jonathan Keith Mason
NPI 1699972174
$6,914.96
in general payments reported to CMS, 2019-2025
27 companies · $570 in 2025
The $570 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $150 · 2021: $283 · 2022: $708 · 2023: $905 · 2024: $3,957 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,200 · Food and Beverage: $2,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,200.00 |
| Food and Beverage | $2,231.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $4,519.77 | 2021-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $678.42 | 2022-2025 | Azstarys, Azstarys |
| Kaleo, INC. | $241.11 | 2019-2024 | Auvi-Q |
| Supernus Pharmaceuticals, INC. | $168.61 | 2021-2023 | Qelbree |
| Sobi, INC | $156.00 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $132.01 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $111.34 | 2019-2025 | |
| Alk-Abello, INC | $107.37 | 2023-2025 | Grastek, Odactra, Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $90.36 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $89.59 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $83.95 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $63.11 | 2022-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $57.90 | 2019-2022 | |
| Neos Therapeutics, LP | $57.63 | 2019-2024 | Adzenys Xr-Odt |
| Ultragenyx Pharmaceutical INC. | $52.37 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $47.82 | 2021-2025 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $44.71 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $37.78 | 2023-2024 | Flumist Quadrivalent |
| Phadia US INC. | $31.78 | 2019-2021 | |
| Genentech USA, INC. | $25.92 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $25.00 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $19.40 | 2025 | Ycanth |
| Kyowa Kirin, INC. | $17.50 | 2023 | Crysvita |
| Shire North American Group INC | $15.07 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.29 | 2019 | |
| Ucb, INC. | $13.75 | 2019 | |
| Adlon Therapeutics L.P. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.